Tower Research Capital LLC TRC Buys 41,269 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Tower Research Capital LLC TRC increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 958.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,576 shares of the company’s stock after acquiring an additional 41,269 shares during the quarter. Tower Research Capital LLC TRC’s holdings in ARS Pharmaceuticals were worth $481,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals during the fourth quarter worth $73,000. Compass Capital Corp MA ADV acquired a new stake in ARS Pharmaceuticals during the 4th quarter worth $106,000. Teacher Retirement System of Texas bought a new position in ARS Pharmaceuticals during the fourth quarter worth about $122,000. Amica Mutual Insurance Co. acquired a new position in ARS Pharmaceuticals in the fourth quarter valued at about $151,000. Finally, PEAK6 LLC bought a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth about $162,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Laura Shawver sold 50,002 shares of the firm’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,587,255.80. This represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 159,602 shares of company stock worth $1,926,541 over the last 90 days. Company insiders own 40.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SPRY shares. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Raymond James upped their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Oppenheimer started coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Leerink Partners lifted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Stock Down 1.6 %

Shares of ARS Pharmaceuticals stock opened at $13.92 on Wednesday. ARS Pharmaceuticals, Inc. has a 12-month low of $7.55 and a 12-month high of $18.51. The business’s 50 day moving average is $12.61 and its 200-day moving average is $13.07. The stock has a market cap of $1.37 billion, a P/E ratio of -27.29 and a beta of 0.86.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. On average, sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.